Sandoz cross-claim seeks to block Merck Sharp & Dohme’s Januvia patent extension

Clare Cunliffe 2021-03-09 1:51 pm By Miklos Bolza | Sydney

Please login to bookmark

Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au